Incyte CORP Form 4 insider transactions

Incyte Corporation's Executive Vice President and General Counsel, Sheila A. Denton, engaged in a pre-planned transaction involving the exercise of stock options and the subsequent sale of common stock on July 2, 2025.

Incyte Corporation's Executive Vice President, Vijay K. Iyengar, reported the sale of 15,426 shares of common stock in early July 2025, including shares withheld for tax obligations, all executed under a Rule 10b5-1 trading plan.

Incyte Corp's Director and Special Advisor to the CEO, Herve Hoppenot, reported a pre-planned disposition of 42,769 common shares at $68.17 per share scheduled for July 2, 2025, primarily for tax withholding related to RSU and performance share settlements.

Julian C. Baker, a director of Incyte Corporation and representative of Baker Bros. entities, received 492 shares of Incyte common stock as quarterly director retainer fees, leading to updated beneficial ownership disclosures for associated funds and individuals.

Incyte Corporation Director Paul J. Clancy acquired 361 shares of common stock at $68.10 per share on June 30, 2025, as part of his director compensation.

Incyte Corp. Director Edmund Harrigan acquired 367 shares of common stock at $68.10 per share on June 30, 2025, as part of his quarterly director retainer fees under a Rule 10b5-1 plan.

Mohamed Khairie Issa, EVP, Head of US Oncology at Incyte Corp, was granted 27,812 restricted stock units, increasing his total unvested RSU holdings to 76,483 shares.

Incyte Corporation's Chief Executive Officer, William Meury, was granted 36,101 restricted stock units and performance shares totaling up to 233,303 common shares, contingent on performance and vesting conditions.

Incyte Corporation's Chief Executive Officer, William Meury, was granted 110,630 employee stock options with an exercise price of $70.81, vesting over approximately four years.

Incyte Corporation's Director and Special Advisor to the CEO, Herve Hoppenot, was granted significant equity awards including restricted stock units, stock options, and performance shares on June 26, 2025.

Incyte Corporation Director Jean-Jacques Bienaime reported the acquisition of 2,518 restricted stock units and 9,216 non-qualified stock options on June 10, 2025, as part of his compensation.

Incyte Corporation Director Otis W. Brawley reported the acquisition of 2,518 restricted stock units and 9,216 non-qualified stock options as part of compensation on June 10, 2025.

Incyte Corporation Director Jacqualyn A. Fouse was granted 2,518 restricted stock units and 9,216 non-qualified stock options on June 10, 2025, as part of her compensation, increasing her total beneficial ownership.

Incyte Corporation Director Katherine A. High was granted 2,518 restricted stock units and 9,216 non-qualified stock options as part of her compensation, aligning her interests with shareholder value.

Incyte Corporation's director, Julian C. Baker, was granted 2,518 restricted stock units and 9,216 non-qualified stock options as part of his compensation, as detailed in a recent SEC Form 4 filing.

Incyte Corporation's Director, Paul J. Clancy, was granted 2,518 restricted stock units and options to purchase 9,216 shares of common stock as part of his compensation.

Incyte Corporation Director Susanne Schaffert reported the acquisition of 2,518 restricted stock units and 9,216 non-qualified stock options, alongside the disposition of 849 shares for tax withholding, as detailed in a recent SEC Form 4 filing.

Incyte Corp. Director Edmund Harrigan was granted 2,518 restricted stock units and 9,216 non-qualified stock options, aligning his interests with shareholders.

Sheila A. Denton, Incyte Corp's EVP & General Counsel, exercised stock options and simultaneously sold an equivalent number of shares as part of a pre-arranged Rule 10b5-1 plan.

Incyte Corp's Principal Accounting Officer, Tray Thomas, sold a total of 1,614 shares of common stock in two transactions in late May and early June 2025, pursuant to a Rule 10b5-1 trading plan.

EVP and General Manager of Incyte, Barry P. Flannelly, reports the acquisition of common stock related to performance shares, with vesting contingent on continued service and retirement provisions.

EVP Vijay K. Iyengar reports acquisition and disposal of Incyte common stock related to performance shares.

EVP Michael Morrissey acquired 4,649 shares of Incyte common stock on April 1, 2025, based on the achievement of performance criteria, with vesting contingent on continued service.

Christiana Stamoulis, EVP & Chief Financial Officer of Incyte Corp, reports the acquisition of common stock related to performance shares, increasing her beneficial ownership.

EVP & Chief Medical Officer of Incyte, Steven H. Stein, reports transactions involving Incyte common stock related to performance shares.

Paula Swain, EVP of Human Resources at Incyte Corp, reports the acquisition of common stock related to performance shares, with vesting conditions tied to continued service and achievement of performance goals.

Herve Hoppenot, Chairman and CEO of Incyte Corp, reports acquiring 66,899 shares of common stock on April 1, 2025, related to performance shares.

Baker Bros. Advisors LP reports changes in beneficial ownership of Incyte Corp shares due to director retainer fees and other transactions.

Director Paul J Clancy acquired 358 shares of Incyte Corp common stock at $60.55 per share on March 31, 2025, under the company's Amended and Restated 2010 Stock Incentive Plan.

Director Edmund Harrigan reports acquisition of Incyte common stock and discloses beneficial ownership following the transaction.